Amarin Stock Moves Higher As Vascepa Cuts Risk Of Heart Attacks

Amarin Corporation plc AMRN announced additional data on Vascepa/Vazkepa (icosapent ethyl) in patients with prior heart attack, known as myocardial infarction (MI), at risk for major adverse cardiovascular events.
The data were presented at the European Society of Cardiology.
The investigators concluded that "Icosapent ethyl 4 g/day significantly reduced first and total primary endpoints of a 5-point major adverse cardiovascular event (MACE), comprised of CV death, MI, stroke, coronary revascularization, and hospitalization for unstable angina by 26% and 35%, respectively.
Icosapent ethyl led to generally robust reductions across the prespecified hierarchy of secondary endpoints and in sudden cardiac death and cardiac arrest.
Price Action: AMRN shares are up 9.09% at $5.88 during the market session on the last check Monday.